Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant
Purpose. To assess short-term functional and anatomical outcomes of refractory diabetic macular edema (DME) following a switch from ranibizumab or dexamethasone to aflibercept. Methods. We included retrospectively eyes with persistent DME after at least 3 ranibizumab and/or one dexamethasone implant...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2017/8035013 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841524727446765568 |
|---|---|
| author | Antoine Herbaut Franck Fajnkuchen Lise Qu-Knafo Sylvia Nghiem-Buffet Bahram Bodaghi Audrey Giocanti-Auregan |
| author_facet | Antoine Herbaut Franck Fajnkuchen Lise Qu-Knafo Sylvia Nghiem-Buffet Bahram Bodaghi Audrey Giocanti-Auregan |
| author_sort | Antoine Herbaut |
| collection | DOAJ |
| description | Purpose. To assess short-term functional and anatomical outcomes of refractory diabetic macular edema (DME) following a switch from ranibizumab or dexamethasone to aflibercept. Methods. We included retrospectively eyes with persistent DME after at least 3 ranibizumab and/or one dexamethasone implant intravitreal injections (IVI). The primary endpoint was the mean change in visual acuity (VA) at month 6 (M6) after switching. Results. Twenty-five eyes were included. Before switching to aflibercept, 23 eyes received a median of 9.5 ranibizumab, and among them, 6 eyes received one dexamethasone implant after ranibizumab and 2 eyes received only one dexamethasone implant. Baseline VA, before any IVI, was 52.9 ± 16.5 letters, and preswitch VA was 57.1 ± 19.6 letters. The mean VA gain was +8 letters (p=0.01) between preswitch and M6. The mean central retinal thickness was 470.8 ± 129.9 μm before the switch and 303.3 ± 59.1 μm at M6 (p=0.001). Conclusion. Switching to aflibercept in refractory DME results in significant functional and anatomical improvement. The study was approved by the France Macula Federation ethical committee (FMF 2017-138). |
| format | Article |
| id | doaj-art-5f020d3cd47c4c4980f486bd50684130 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-5f020d3cd47c4c4980f486bd506841302025-02-03T05:47:33ZengWileyJournal of Ophthalmology2090-004X2090-00582017-01-01201710.1155/2017/80350138035013Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone ImplantAntoine Herbaut0Franck Fajnkuchen1Lise Qu-Knafo2Sylvia Nghiem-Buffet3Bahram Bodaghi4Audrey Giocanti-Auregan5Ophthalmology Department, Avicenne Hospital, DHU Vision and Handicaps, Paris XIII University, 125 rue de Stalingrad, 93000 Bobigny, FranceOphthalmology Department, Avicenne Hospital, DHU Vision and Handicaps, Paris XIII University, 125 rue de Stalingrad, 93000 Bobigny, FranceOphthalmology Department, Avicenne Hospital, DHU Vision and Handicaps, Paris XIII University, 125 rue de Stalingrad, 93000 Bobigny, FranceOphthalmology Department, Avicenne Hospital, DHU Vision and Handicaps, Paris XIII University, 125 rue de Stalingrad, 93000 Bobigny, FranceOphthalmology Department, Avicenne Hospital, DHU Vision and Handicaps, Paris XIII University, 125 rue de Stalingrad, 93000 Bobigny, FranceOphthalmology Department, Avicenne Hospital, DHU Vision and Handicaps, Paris XIII University, 125 rue de Stalingrad, 93000 Bobigny, FrancePurpose. To assess short-term functional and anatomical outcomes of refractory diabetic macular edema (DME) following a switch from ranibizumab or dexamethasone to aflibercept. Methods. We included retrospectively eyes with persistent DME after at least 3 ranibizumab and/or one dexamethasone implant intravitreal injections (IVI). The primary endpoint was the mean change in visual acuity (VA) at month 6 (M6) after switching. Results. Twenty-five eyes were included. Before switching to aflibercept, 23 eyes received a median of 9.5 ranibizumab, and among them, 6 eyes received one dexamethasone implant after ranibizumab and 2 eyes received only one dexamethasone implant. Baseline VA, before any IVI, was 52.9 ± 16.5 letters, and preswitch VA was 57.1 ± 19.6 letters. The mean VA gain was +8 letters (p=0.01) between preswitch and M6. The mean central retinal thickness was 470.8 ± 129.9 μm before the switch and 303.3 ± 59.1 μm at M6 (p=0.001). Conclusion. Switching to aflibercept in refractory DME results in significant functional and anatomical improvement. The study was approved by the France Macula Federation ethical committee (FMF 2017-138).http://dx.doi.org/10.1155/2017/8035013 |
| spellingShingle | Antoine Herbaut Franck Fajnkuchen Lise Qu-Knafo Sylvia Nghiem-Buffet Bahram Bodaghi Audrey Giocanti-Auregan Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant Journal of Ophthalmology |
| title | Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant |
| title_full | Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant |
| title_fullStr | Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant |
| title_full_unstemmed | Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant |
| title_short | Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant |
| title_sort | switching to aflibercept in diabetic macular edema not responding to ranibizumab and or intravitreal dexamethasone implant |
| url | http://dx.doi.org/10.1155/2017/8035013 |
| work_keys_str_mv | AT antoineherbaut switchingtoafliberceptindiabeticmacularedemanotrespondingtoranibizumabandorintravitrealdexamethasoneimplant AT franckfajnkuchen switchingtoafliberceptindiabeticmacularedemanotrespondingtoranibizumabandorintravitrealdexamethasoneimplant AT lisequknafo switchingtoafliberceptindiabeticmacularedemanotrespondingtoranibizumabandorintravitrealdexamethasoneimplant AT sylvianghiembuffet switchingtoafliberceptindiabeticmacularedemanotrespondingtoranibizumabandorintravitrealdexamethasoneimplant AT bahrambodaghi switchingtoafliberceptindiabeticmacularedemanotrespondingtoranibizumabandorintravitrealdexamethasoneimplant AT audreygiocantiauregan switchingtoafliberceptindiabeticmacularedemanotrespondingtoranibizumabandorintravitrealdexamethasoneimplant |